ReviewJournal of clinical medicine2024
Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- Assessing the mortality burden after acute myocardial infarction in SLE: insights from the MINAP Registry.Rheumatology (Oxford, England) · 2026Article
- Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.Circulation research · 2026Article
- A Novel Approach to Gastrointestinal Bleeding Risk Stratification and Proton Pump Inhibitor Effectiveness in Patients with Acute Coronary Syndrome on Dual Antiplatelet Therapy: A Nationwide Retrospective Cohort Study.Cardiovascular drugs and therapy · 2026Article
- Clinical practice of cangrelor use in Austrian ACS patients: a real-world multicenter registry.Frontiers in cardiovascular medicine · 2026Article
- The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches.Current issues in molecular biology · 2025Review
- Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study.BMC cardiovascular disorders · 2025Article
- Optical Coherence Tomography in Myocardial Infarction Management: Enhancing Precision in Percutaneous Coronary Intervention.Journal of clinical medicine · 2024Review
- Antiplatelet Effects of a Combination of Sappan Wood (Advances in pharmacological and pharmaceutical sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.